Previous Article | Next Article 
Journal of Virology, March 2000, p. 2777-2785, Vol. 74, No. 6
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Infectious Entry Pathway of Adeno-Associated Virus
and Adeno-Associated Virus Vectors
Jeffrey S.
Bartlett,1,2,3,4,*
Rose
Wilcher,1 and
R. Jude
Samulski1,5
Gene Therapy Center,1
Pulmonary and Cystic Fibrosis Research Center, Department of
Medicine,2 and Department of
Pharmacology,5 The University of North Carolina
at Chapel Hill, Chapel Hill, North Carolina, and Children's
Research Institute, Children's Hospital,3 and
Division of Molecular Medicine, Department of Pediatrics,
College of Medicine and Public Health, The Ohio State
University,4 Columbus, Ohio
Received 16 August 1999/Accepted 16 December 1999
 |
ABSTRACT |
We have investigated the infectious entry pathway of
adeno-associated virus (AAV) and recombinant AAV vectors by assessing AAV-mediated gene transfer and by covalently conjugating fluorophores to AAV and monitoring entry by fluorescence microscopy. We examined AAV
entry in HeLa cells and in HeLa cell lines which inducibly expressed a
dominant interfering mutant of dynamin. The data demonstrate that AAV
internalizes rapidly by standard receptor-mediated endocytosis from
clathrin-coated pits (half-time <10 min). The lysosomotropic agents
ammonium chloride and bafilomycin A1 prevent AAV-mediated gene transfer when present during the first 30 min after the onset of
endocytosis, indicating that AAV escapes from early endosomes yet
requires an acidic environment for penetration into the cytosol. Following release from the endosome, AAV rapidly moves to the cell
nucleus and accumulates perinuclearly beginning within 30 min after the
onset of endocytosis. We present data indicating that escape of AAV
from the endosome and trafficking of viral particles to the nucleus are
unaffected by the presence of adenovirus, the primary helper virus for
a productive AAV infection. Within 2 h, viral particles could be
detected within the cell nucleus, suggesting that AAV enters the
nucleus prior to uncoating. Interestingly, the majority of the
intracellular virus particles remain in a stable perinuclear
compartment even though gene expression from nuclear AAV genomes can be
detected. This suggests that the process of nuclear entry is rate
limiting or that AAV entry involves multiple pathways. Nevertheless,
these data establish specific points in the AAV infectious entry
process and have allowed the generation of a model for future expansion
to specific cell types and AAV vector analysis in vivo.
 |
INTRODUCTION |
Gene transfer vectors based on
adeno-associated virus type 2 (AAV-2) show great promise for use in
human gene therapy. Several clinical trials using these reagents have
recently commenced, and a number of patients have already been treated.
Although the clinical success of this relatively new vector system has
yet to be established, important information has been gained from these
as well as a number of earlier, preclinical studies. While AAV can
efficiently transfer genes to a number of different cell types (muscle,
brain, and liver) (36), it is apparent that there are
obstacles which can limit transduction of certain cell types in vivo
(2, 17, 31, 44). The further development of AAV-based gene
therapy vectors will likely benefit from a more detailed understanding
of the interactions between these vectors and target cells and the
implications of these interactions to successful gene transfer.
Recently, the cellular receptors which define the cell types
potentially amenable to AAV-mediated gene therapy have been described
(30, 40, 41). However, the mechanisms by which AAV vectors
are taken up into cells, translocated to the nucleus, and positioned
within the cell such that their transgenes can be expressed are still
poorly understood.
Viral receptors are often involved in defining the host range and
specific tissue tropism of a virus. Recently, biochemical and genetic
evidence has been provided which suggests that cell surface heparan
sulfate proteoglycan (HSPG) serves as the primary attachment receptor
for AAV (41). Fibroblast growth factor receptor and
v
5 integrin have also been implicated as
coreceptors or facilitators of AAV entry into target cells (30,
40). However, little is known about the process of AAV infection
following attachment to the cell surface. In fact, the mechanism of
entry for most nonenveloped viruses is not well understood. Several
different mechanisms have been suggested based on morphological,
ultrastructural, and biochemical studies. Direct penetration upon
interaction with the plasma membrane has been suggested for some
nonenveloped viruses, such as rotavirus (20), whereas other
nonenveloped viruses (e.g., adenovirus, reovirus, poliovirus, and
rhinovirus) are believed to follow, at least initially, the same
intracellular route as that described for the enveloped viruses
(25, 29, 39, 46-48). A common paradigm for these viruses
involves binding to a cell surface receptor followed by
receptor-mediated endocytosis and endosome release. Although little is
known about the entry of AAV, a few studies of the related autonomous
parvoviruses, canine parvovirus and minute virus of mice, have been
conducted. Minute virus of mice was reported to bind to both
specialized (coated pits) and unspecified regions of the cell membrane,
and ultrastructural studies have suggested that its internalization
occurs via coated pits (24). Similarly, canine parvovirus
has been shown to be taken up into cells via small endocytic vesicles
and quickly released from these vesicles into the cytoplasm (3,
4). The release of these viruses may take place upon
acidification of the vesicle. However, the mechanism and time course of
this release from the endosomal compartments remain unclear.
Furthermore, the mechanism and time course by which the viral
particles, once released into the cytoplasm, travel to the nucleus for
expression is unknown. The focus of this study was to evaluate the
infectious entry pathway of AAV following attachment of the virus to
the cell surface. To accomplish this, we have developed methods of
conjugating fluorophores directly to the AAV capsid while preserving
the ability of the virus to interact with the cell in a normal manner.
Using AAV-2 and recombinant AAV-2-based vectors as a model to interact
with and transfer genes into HeLa cells in vitro, the data presented here describe the early steps of AAV entry into human cells.
During these analyses we observed that bound AAV particles enter
the cell very rapidly via receptor-mediated endocytosis through
clathrin-coated pits, that release of the virus into the cytosol occurs
within 30 min postinfection and requires endosomal acidification, and that translocation of virus particles results in rapid perinuclear accumulation followed by slower entry into the cell nucleus. These observations begin to define a paradigm for AAV and AAV vector entry in
target cells which should impact the utility of these reagents for
human gene therapy by providing a molecular understanding of
rate-limiting steps required for successful gene transduction.
 |
MATERIALS AND METHODS |
Cell culture.
HeLa and 293 cells, which have been described
elsewhere (12, 14), were obtained from the American Type
Culture Collection, Manassas, Va. and maintained in Dulbecco's
modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated
fetal bovine serum (FBS), penicillin (100 U/ml), and streptomycin (100 µg/ml) (GIBCO, Grand Island, N.Y.) at 37°C in a 5% CO2
atmosphere. For microscopy, cells were seeded onto two-well chambered
tissue culture treated glass slides (Falcon) at a density of
104 cells per chamber or onto four-well chambered cover
glasses at a density of 5 × 103 cells per chamber and
were used 24 to 48 h later. Chambered cover glasses were coated
with poly-D-lysine (Sigma; 0.1 mg/ml; 1 h) prior to
use. For confocal microscopy, HeLa S3 cells were grown in modified
essential medium (S-MEM; GIBCO) containing 5% horse serum and 5% FBS.
HeLa cells expressing wild-type or the K44A mutant form of dynamin
under tetracycline-inducible control (tTA-HeLa) were kind gifts from
Sandra Schmid (Scripps Research Institute, La Jolla, Calif.)
(9) and were initially maintained in DMEM supplemented with
10% heat-inactivated FBS, 400 µg of gentamicin/ml, 200 ng of
puromycin/ml, and 1 µg of tetracycline/ml. For induction of dynamin
overexpression, the cells were cultured in the absence of tetracycline
for 2 days before being exposed to AAV.
Viruses and vector production and assay.
Adenovirus
dl309 (19) has been described previously. Plasmid
psub201, used to generate wild-type AAV, and plasmid pAB-11, used to
generate AAVlacZ, have been described previously (13, 35).
Plasmid pTRUF-5, kindly provided by Sergei Zolotukhin and Nicholas
Muzyczka (University of Florida), was used to generate AAVEGFP. Both
recombinant AAV vectors express transgenes under the control of the
cytomegalovirus immediate-early promoter-enhancer. AAV vectors were
produced in the absence of helper virus in 293 cells and purified
either by successive bandings on CsCl gradients (23, 38) or
by heparan sulfate (HS) affinity chromatography (8, 49).
Wild-type AAV was prepared in adenovirus-infected cells by transfection
of psub201 plasmid DNA as described previously (34). For
preparation of fluorescently labeled AAV, the purity of virus was
assessed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) to ensure that adenovirus and cellular proteins had been
completely removed. Preparations containing material other than the
three AAV nonstructural proteins to the limit of detection either were
further purified or were discarded because they proved unsatisfactory
for fluorescence labeling. Purified virus particles were dialyzed into
10 mM Tris-150 mM NaCl (pH 7.8) containing 10% glycerol and frozen at
80°C until required for use. Particle numbers for wild-type AAV
were determined by protein quantitation (7.5 µg of protein is
equivalent to 1012 particles). The titer of the recombinant
virus, expressed as 293 cell transducing units, was determined by
infecting 293 cells in the presence of adenovirus (dl309)
and staining for
-galactosidase activity at 36 h
(37). Radiolabeled AAV was prepared by adding [3H]methylthymidine (Amersham; 1 µCi/ml final
concentration) to 293 cells 8 h after adenovirus
(dl309) and wild-type AAV infection. The infected cells were
harvested at 48 h postinfection, and the virus was purified as
described above. The activity of the labeled virus was approximately
2 × 10
7 cpm per virus particle.
Fluorescent probes.
Purified virus was labeled with the
carbocyanine dyes Cy2 and Cy3 (Amersham). Labeled AAV was prepared by
adjusting AAV stocks to a concentration of 1 mg/ml (1.33 × 1014 particles/ml) in sodium carbonate-sodium bicarbonate
buffer, pH 9.3. Buffer exchange was accomplished by rapid dialysis or by gel filtration on Sephadex G-50 (Pharmacia) spin columns. One milliliter of virus preparation was used to reconstitute the labeling reagent. After 30 min at room temperature, labeled virus was purified by extensive dialysis against 10 mM Tris (pH 7.8)-150 mM NaCl with
10% glycerol, by gel filtration on Sephadex G-50 using the same
buffer, or by HS affinity chromatography. The purified virus was
aliquoted into single-use vials and stored at
80°C prior to use.
Labeled AAV was analyzed by SDS-PAGE to determine the specificity of
the labeling reaction and the degree of protein cross-linking.
Dye concentration was determined spectrophotometrically, using a
molar extinction coefficient of 150,000 M
1
cm
1 at 552 nm for the Cy3 dye and an experimentally
determined molar extinction coefficient at 280 nm for purified
unlabeled AAV particles. Cy3-labeled adenovirus (Cy3Ad) was prepared as
described by Leopold et al. (22).
Virus infections.
HeLa cells were infected with 1.25 × 1011 particles of Cy3-conjugated AAV (Cy3AAV)/ml
(approximately 106 particles/cell) in binding buffer (DMEM
containing 2 mM glucose, 10 mM HEPES [pH 7.3], and 1% bovine serum
albumin) at 37°C unless otherwise noted. Cells were washed three
times with binding buffer prior to infection. Lengths of viral exposure
are noted but usually consisted of a short, 10-min pulse, after which
the cells were washed twice with acid wash buffer [50 mM
2-(N-morpholino)ethanesulfonic acid (MES)-280 mM sucrose,
pH 5] and three times with binding buffer. After being washed, the
cells were either fixed immediately or maintained at 37°C during
additional incubation periods. Prior to fixation, the binding buffer
was removed and the cells were washed three times with ice-cold
phosphate buffered saline (PBS; GIBCO, Grand Island, N.Y.). Cells
were fixed with 4% paraformaldehyde in PBS for 15 min at room
temperature and washed three times with PBS. Where indicated,
cells were either treated for 5 min at room temperature with 1-µg/ml
DAPI (4',6'-diamidino-2-phenylindole; Molecular Probes, Inc., Eugene,
Oreg.) in PBS-0.1% Triton X-100 and washed three times with PBS or
mounted in medium containing DAPI (VECTASHIELD; Vector Laboratories,
Inc., Burlingame, Calif.). In some experiments, cells were treated with
25 nM ammonium chloride or bafilomycin A1 (Sigma) as indicated.
Fluorescence microscopy.
Images were collected by the use of
a Leica DMIRB microscope equipped with 40× NA 0.7 PlanApo DIC, 60× NA
1.4 PlanApo DIC, and 100× NA 1.4 PlanApo DIC objectives and a
Hamamatsu intensified cooled charge-coupled device camera. The 16-bit
images were digitally enhanced by subtraction of background and by
gray-scale adjustment.
 |
RESULTS |
Characterization of fluorescently labeled virus.
Fluorescently
labeled AAV was generated to study the viral entry pathway within the
host cell. We characterized this reagent extensively in order to
validate wild-type AAV entry steps. Virus labeled with cyanine-based
reagents was readily visualized within HeLa cells after viral infection
by standard fluorescence microscopy (Fig.
1). Since the fluorescent labeling of the
virus involved the covalent modification of the capsid and exposure of
virus to harsh conditions (pH 9.3), we were concerned that this process might alter the biological or physical properties of the viral particles. Although the attachment of fluorophore led to a small amount
of protein cross-linking (less than 5%, as assessed by SDS-PAGE) (Fig.
2A), specificity for the viral receptor
(Fig. 2B), virus attachment (Fig. 1 and 2C), and virus internalization (Fig. 1) were unchanged. Labeled virus particles that maintained normal
physical and biological properties had dye-to-viral particle ratios in
the range of 1.6 to 2.3 (n = 4). There were no
detrimental effects on the physical properties of the viral particles
(Fig. 2) or significant biological effects as evidenced by changes in viral titer (~2 × 1011 infectious units/ml both
prior to and following fluorescence labeling). However, at
dye-to-particle ratios above the specified range, e.g., >4
(n = 2), titers were severely affected and virus particles were prone to aggregation and precipitation. For this reason,
all studies were carried out with AAV labeled at a dye-to-particle ratio of approximately 2. It should also be noted that by SDS-PAGE analysis it was shown that only viral capsid proteins were labeled with
fluorophore. Fluorophore was not seen associated with cellular proteins
or with any of the nonstructural viral proteins (Fig. 2a). However, it
must be stressed that to achieve this level of specificity it was
necessary to extensively purify AAV virions. Virus was purified either
on three successive CsCl gradients or by a combination of CsCl gradient
purification and HS affinity chromatography prior to labeling.
Furthermore, all preparations were carefully monitored for the presence
of degraded viral proteins or cellular proteins by SDS-PAGE to
ensure specificity of the final labeled AAV preparation. The
specificity and quality of the labeled virus are demonstrated by
the ability to compete cell-associated Cy3AAV-2 fluorescence on HeLa
cells with either excess unlabeled virus (Fig. 2C) or soluble HS (Fig.
2B). These results also demonstrate that the labeling reaction has not
altered the ability of the virus to interact with its primary
attachment receptor on the cell surface. Further evidence that
fluorescent AAV has maintained its dependence on HSPG-mediated
attachment was demonstrated by our ability to repurify labeled virus
via HS affinity chromatography and by the cell binding profile of these
reagents for HSPG-deficient cell lines (41). Validation of
the labeled virions as described above provided a unique reagent to
assay entry mechanisms of AAV infection.

View larger version (95K):
[in this window]
[in a new window]
|
FIG. 1.
Uptake of Cy3AAV-2 by HeLa cells. HeLa cells were
incubated with 1.25 × 1011 particles of Cy3AAV-2/ml
for 10 min at 37°C, washed to remove virus particles that had not
internalized, and maintained at 37°C for 30 min. Labeled virus was
visualized by fluorescence microscopy. Bar, 10 µm.
|
|

View larger version (39K):
[in this window]
[in a new window]
|
FIG. 2.
Characterization of Cy3-labeled AAV particles: Cy3AAV-2
maintains dependence on HSPG-mediated attachment. (A) SDS-PAGE analysis
of labeled capsid proteins (lane 1) and unmodified capsid proteins
(lane 2). Protein cross-linking due to the labeling reaction was less
than 5%. (B) Quantitative assessment of cell-associated Cy3
fluorescence intensity following coincubation of HeLa cells with
Cy3AAV-2 and increasing amounts of heparin. (C) Assessment of
cell-associated Cy3 fluorescence by fluorescence-activated cell sorter
analysis. HeLa cells were incubated with 2.5 × 1010
particles of Cy3AAV-2/ml for 30 min at 4°C (left panel) or with
2.5 × 1010 particles of Cy3AAV-2/ml in the presence
of 5 × 1012 particles of unlabeled AAV-2 (wtAAV2) for
30 min at 4°C (right panel). Both sets of cells were then washed,
fixed, and directly subjected to flow-cytometric analysis.
|
|
AAV is rapidly internalized via clathrin-coated pits.
Virus
internalization was monitored by using both fluorescently and
radioactively labeled AAV-2. However, the use of 3H-labeled
virus allowed easier quantification of AAV entry. HeLa cells, which
express AAV attachment receptors (HSPG) at high levels, were incubated
with [3H]AAV-2 at 4°C for 60 min, washed to eliminate
unattached virus, and then incubated at 37°C for different lengths of
time (0 to 90 min). Virus particles that had not been internalized were
removed from the cell surface by washing with a mildly acidic buffer, and cell-associated radioactivity was determined by scintillation counting. More than 60% of the bound virus particles were taken up
into the cells within the first 10 min of incubation at 37°C (Fig.
3). Thus, the internalization half-time
for AAV is less than 10 min. Although this rapid entry of AAV into the
host cells is indicative of receptor-mediated endocytosis, it was of
interest to determine whether productive infection by AAV requires
endocytosis from clathrin-coated pits. The recent identification of
host cell proteins that regulate clathrin-mediated endocytosis provided an opportunity to more precisely define the mechanism of AAV entry.

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 3.
Internalization of AAV-2 by HeLa cells. HeLa cells were
incubated with [3H]AAV-2 at 4°C for 60 min, washed to
remove unattached virus, and then incubated at 37°C for various
lengths of time (0 to 90 min). Virus that had not internalized was
removed from the cell surface by washing with a mildly acidic buffer,
and cell-associated radioactivity was determined by scintillation
counting. Values shown are means ± standard error and have been
adjusted by subtraction of background radioactivity (n = 3).
|
|
Dynamin is a 100-kDa cytosolic GTPase that selectively regulates
clathrin-mediated endocytosis. Dynamin associates with
clathrin-coated
membrane invaginations and has been
proposed to mediate the constriction
of coated pits and the
budding of coated vesicles from the plasma
membrane (
18,
43). A dominant-negative mutant form of dynamin
containing a
point mutation in the GTP binding domain (Lys-44
to Ala-44
[K44A]) has been shown to block clathrin-mediated endocytosis
(
9). AAV infection of HeLa cells expressing the K44A
mutant
dynamin was measured by using the AAVlacZ vector.
Uninduced tTA-HeLa
cells or cells which had been induced by removal of
tetracycline
for 48 h were infected with AAVlacZ at a virus
particle-to-cell
ratio of 1,000:1. The number of cells expressing the
lacZ reporter
gene was then quantitated 48 h
postinfection by
5-bromo-4-chloro-3-indolyl-

-
D-galactopyranoside
(X-Gal)
histochemistry analysis. A significant decrease in AAV-mediated
lacZ transduction was observed in HeLa cells induced for
K44A
expression (minus tetracycline) compared to that evident in
tetracycline-regulated
HeLa cells (Fig.
4, left panel). The level of AAV-mediated
gene
delivery to HeLa cells in the presence of tetracycline was the
same as that to HeLa cells overexpressing wild-type dynamin under
the
control of the tetracycline-regulated promoter (Fig.
4, left
panel).
Furthermore, induction of mutant dynamin 30 min following
infection did
not inhibit reporter gene expression (data not shown),
supporting the
involvement of this protein in AAV entry steps
prior to gene
expression. We also determined that expression of
mutant K44A dynamin,
or overexpression of wild-type dynamin, did
not interfere with virus
attachment by analyzing Cy3AAV-2 binding
to tetracycline-induced
and uninduced HeLa cell lines (Fig.
4,
right panel). Therefore,
inhibition of AAV-mediated gene delivery
was due to decreased
virus uptake and not to inhibition of virus
attachment or vector gene
expression. These findings demonstrate
that the predominant route of
AAV entry into HeLa cells is via
receptor-mediated endocytosis.

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 4.
Entry of AAV-2 is mediated by
dynamin-associated uptake pathways. AAV-2-mediated gene transfer (left
panel) and AAV-2 attachment (right panel) to HeLa cells overexpressing
wild-type (wt) dynamin were compared to those of cells expressing
mutant (K44A) dynamin. Cells were exposed to [3H]AAV-2
(1010 particles/ml) or AAVlacZ (108
particles/ml) for 2 h at 4°C, and either attachment
(3HAAV-2) was measured immediately or gene transfer
(AAVlacZ) was assessed 48 h later. Expression of wild-type or
mutant dynamin was induced by removal of tetracycline from the growth
medium, as described in Materials and Methods. (Left panel)
AAV-2-mediated gene transfer is shown in the presence and absence of
tetracycline; (right panel). AAV-2 binding is shown in the absence of
tetracycline. The specificity of AAV-2 binding was determined by
competition with a 200-fold molar excess of unlabeled virus (wt AAV).
Values shown are means ± standard error (n = 6
for each).
|
|
AAV requires passage through an acidic compartment for productive
infection.
Biochemical studies using the lysosomotropic drug
ammonium chloride (28) or the proton pump inhibitor
bafilomycin A1 (6) showed that these drugs have
a significant inhibitory effect on AAV infectivity and AAV-mediated
gene expression (Fig. 5). These drugs
essentially block infection of HeLa cells when present during the first
30 min after the onset of endocytosis. Ammonium chloride is known to
raise the pH of intracellular organelles within 1 min following
addition (28), making it possible to inhibit a low-pH-dependent endosomal escape mechanism at defined time points. The
inhibitory effect of ammonium chloride on AAV-mediated gene transfer in
HeLa cells is demonstrated in Fig. 5A. This drug did not significantly
influence AAV-mediated gene transfer when present exclusively during
the adsorption phase at 4°C, a temperature that blocks endocytosis,
implying that the presence of ammonium chloride at this time point did
not influence binding of AAV to the plasma membrane. We observed
half-maximal AAV-mediated gene expression when the drug was added 30 min after the cells were warmed to 37°C, suggesting that endosomal
escape had already begun by this time. This observation supports the
occurrence of early endosome escape for AAV virions. Furthermore,
AAV-mediated gene transfer was completely resistant to ammonium
chloride by 90 min after the shift to 37°C, suggesting that
penetration of the virus into the cytosol was complete by this time.


View larger version (2021K):
[in this window]
[in a new window]
|
FIG. 5.
Inhibitory effect of ammonium chloride and bafilomycin
A1 on AAV-mediated gene transfer. (A) AAVlacZ vector was
bound to HeLa cells at 4°C for 120 min, and unbound virions were
washed away. Ammonium chloride (25 mM final concentration) was added at
the indicated time points ( ) and was present during different 2-h
periods as indicated by the horizontal bars. The ammonium chloride was
washed out of the cells at the ends of these periods, and gene transfer
was assessed at 24 h postinfection by X-Gal histochemistry. Values
shown are means ± standard error (n = 3). (B)
HeLa cells grown on chambered slides were preincubated without ( ) or
with bafilomycin A1 (20 or 200 nM) for 30 min at 37°C.
AAVEGFP vector (1010 particles/ml) was allowed to bind to
the cells for 10 min at 37°C, the cells were washed to remove unbound
virus, and vector-mediated green fluorescent protein fluorescence was
assessed by fluorescence microscopy 24 h later. Where indicated,
bafilomycin A1 was present throughout the experiment.
High-level AAV-mediated gene expression was restricted to HeLa cells
grown in the absence of bafilomycin A1.
|
|
To independently confirm the occurrence of early endosome escape by
AAV, we utilized a different drug, bafilomycin A
1, during
AAV vector infection. Bafilomycin A
1 is a potent inhibitor
of
the vacuolar H
+-ATPase responsible for acidification of
endosomal vesicles. The
influence of different bafilomycin
A
1 concentrations on AAV infection
of HeLa cells was
determined. Cells were preincubated with 0,
20, or 200 nM bafilomycin
A
1 and then infected with the AAVEGFP
vector. Infection was
monitored 24 h later by measuring green
fluorescent protein
fluorescence. Both 20 and 200 nM bafilomycin
A
1 completely
inhibited infection of HeLa cells by the AAV vector
(Fig.
5B). These
findings support the requirement of endosomal
acidification and early
endosomal escape for efficient AAV vector
infection.
Entry of AAV and adenovirus via distinct endosomal pathways.
The previous data suggest that AAV is able to penetrate the endosomal
membrane fairly quickly following internalization and that this process
requires passage through an acidic compartment. Recently, we have shown
that
v
5 integrin is involved in the AAV
entry process (40). It is interesting that adenovirus, the AAV helper virus necessary for a productive infection, also requires a
slightly acidic pH and binding of the adenovirus penton base protein to
v
5 integrin in order to efficiently
escape from the endosome (7, 29, 47). Although there is
substantial evidence demonstrating that AAV genomes can be expressed in
host cells in the absence of adenovirus, implying that AAV alone is
capable of penetration into the cytosol, it was of interest to
determine synergism or competition of endosomal escape following
adenovirus and AAV coinfection. Adenovirus has been shown to greatly
enhance transduction of some cells by recombinant AAV vectors due to
its effect on second-strand DNA synthesis (10, 11). By
assessing the fate of fluorescently labeled adenovirus and AAV, we
sought to determine whether these viruses ever colocalized within the host cell such that adenovirus might be in a position to physically assist AAV entry into the cytosol. HeLa cells were coinfected with
Cy2AAV-3 and Cy3Ad, and the distribution of the viruses was monitored
at 10, 20, and 40 min and at 1 h postinfection by fluorescence microscopy. At no time point was there significant colocalization of
the AAV (green) and adenovirus (red) labels (Fig.
6A, top panel). In contrast, coinfection
with Cy2AAV-3 and Cy3AAV-2 resulted in extensive colocalization of the
red and green signals (Fig. 6A, lower panel). While these data do not
provide direct evidence of the presence of multiple AAV particles
within each endosome, they support it. These results further support
the notion that endosomal escape of AAV is efficient and is
unaffected by adenovirus. Interestingly, the very early endosomes all
contain several AAV particles, as evidenced by label colocalization
(yellow signal). This may be indicative of a mechanism of
internalization requiring the grouping of multiple receptor-AAV
complexes on the surface of the host cell prior to entry.

View larger version (61K):
[in this window]
[in a new window]
|
FIG. 6.
Pulse-labeling evaluation of fluorescent AAV
distribution in HeLa cells, demonstrating the lack of intraendosomal
colocalization of AAV and adenovirus following endocytosis and
time-dependent translocation of AAV from the cell membrane to the
perinuclear region. (A) HeLa cells were incubated for 10 min at 37°C
with 1.25 × 1011 particles of Cy2AAV-3/ml plus either
1.25 × 1011 particles of Cy3Ad (top panel) or
1.25 × 1011 particles of Cy3AAV-2 (lower panel)/ml
and assessed for colocalization by fluorescence microscopy.
Colocalization of serotype 2 and 3 AAV, but not of adenovirus and AAV,
was evidenced by yellow signal from overlapping red (Cy3) and green
(Cy2) signals. Bar, 10 µm. (B) HeLa cells were incubated with
1.25 × 1011 particles of Cy3AAV-2/ml for 2 h at
4°C, washed, then incubated at 37°C for 0, 30, 120, or 240 min and
assessed by fluorescence microscopy. The positions of nuclei are
evident in the 4-h panel due to DAPI (blue) staining. Bar, 10 µm.
|
|
Translocation of AAV to the nucleus.
The efficiency of AAV
infection relies to a large extent on the efficient targeting of the
AAV genome to the host cell nucleus following infection. This property
is reflected in the rapid translocation of virions to the nuclear
envelope. Cy3AAV-2 was bound to HeLa cells for 2 h at 4°C. Cells
were then washed to remove unbound virus and either fixed immediately
or incubated for various periods of time at 37°C to examine
redistribution of cell-associated virus (Fig. 6B). Prior to
internalization, AAV virions were distributed evenly on the outside of
the plasma membrane (Fig. 6B, 0 min). Following 30 min at 37°C, AAV
exhibited a disperse, punctate distribution in the cell, likely
reflecting virions in both endocytic compartments and free within the
cytosol (Fig. 6B, 30 min). The distribution of staining had already
started to shift toward the nucleus, with some virus beginning to
accumulate at the nuclear envelope; however, the majority of the
virions remained widely distributed in the cytoplasm. Later time points
show a progressive perinuclear accumulation of AAV virions (Fig. 6B,
2 h and 4 h). By 2 h following internalization, nearly
all of the virus particles had accumulated perinuclearly, and they
remained at this location throughout the 4-h incubation period.
To more accurately access the intracellular distribution of AAV and to
determine the potential for nuclear uptake of AAV virions,
we used a
laser scanning confocal microscope. In this manner,
we were able to
demonstrate fluorescent AAV particles within the
nuclei of host cells
within 2 h postinfection (Fig.
7).
These
observations support a rapid transport of capsid components to
the nucleus with transgene expression detected within 3 to 4 h
postinfection (data not shown).

View larger version (51K):
[in this window]
[in a new window]
|
FIG. 7.
Distribution of Cy3AAV-2 particles in HeLa cells 2 h postinfection. HeLa S3 cells were pulsed-labeled with 1.25 × 1011 particles of Cy3AAV-2 (red)/ml for 10 min at 37°C,
washed to remove uninternalized virus, and incubated at 37°C for
2 h prior to analysis by confocal microscopy. The position of the
cell nucleus was assessed by DAPI (blue) staining. A representative
image is shown, consisting of a single plane of focus through the
center of a cell.
|
|
 |
DISCUSSION |
In this study, we established a number of parameters involved in
the early steps of AAV entry, including the use of clathrin-coated pits, a requirement for endosome acidification, escape from endosomal vesicles, and perinuclear accumulation and nuclear translocation of
virions. These data, combined with recent studies (30, 40, 41) related to AAV receptor usage, have allowed us to propose a
model for AAV infection of human cells (Fig.
8). AAV first binds to HSPG on the cell
surface (41) (Fig. 8A). This process may be enhanced by the
presence of fibroblast growth factor receptor (30).
Following binding, AAV is rapidly internalized by clathrin-mediated endocytosis (Fig. 8B) through a process that is aided by the presence of
v
5 integrin (40). Following
internalization into the early endosome, the virus encounters a weakly
acidic environment which is sufficient to allow penetration into
the cytosol either from this compartment or after transport to
another, as-yet-unidentified vesicular compartment (Fig. 8C). Following
release into the cytosol, AAV accumulates perinuclearly
(Fig. 8D) and slowly penetrates through the nuclear pore complex (NPC)
into the nucleus (Fig. 8E). The data generated in our study
provide a working template for further confirmation of this model.

View larger version (65K):
[in this window]
[in a new window]
|
FIG. 8.
Schematic representation of AAV entry and endocytic
trafficking in HeLa cells. Following binding to cell surface HSPG (A),
AAV is rapidly internalized via clathrin-coated pits (B) through a
process involving v 5 integrin. Once
internalized, the virus encounters a weakly acidic environment which is
sufficient to allow penetration into the cytosol (C). Following
endosome release, AAV accumulates perinuclearly (D) and slowly
penetrates through the NPC into the nucleus (E).
|
|
Based on the work of others which demonstrated the feasibility of
direct fluorophore conjugation for the labeling of adenovirus (15,
16, 22), we sought to use a similar approach for the labeling of
AAV in order to monitor viral infection. Critical to the success of
this effort was the fact that AAV virions labeled with the carbocyanine
dyes Cy2 and Cy3 maintained all viral functions, including binding
specificity, internalization, escape from endosomes, translocation to
the nucleus, and nuclear entry. Previously, the use of
fluorophore-conjugated AAV to evaluate extracellular vector interactions with target cells verified the concept of AAV-2 binding to
cell surface HSPG (1, 41) and the role of integrin
v
5 in viral infection (40).
However, more importantly, in this study the use of the fluorescent
virus enabled the determination intracellular pathways of viral
infection and additional key aspects of virus entry.
The experimental data support AAV internalization from clathrin-coated
pits by receptor-mediated endocytosis. After attachment to the cell,
the virions were rapidly cleared from the cell surface, and after 7 to
8 min, half of the surface-bound virions had internalized (Fig. 3).
This time course of AAV entry is very similar to that established for
adenovirus. Since adenovirus is often presented as a model nonenveloped
virus which enters cells by receptor-mediated endocytosis, our results
are in good agreement with this paradigm (29, 45-47).
Furthermore, we present for the first time a molecular view of how
these two viruses proceed through a productive coinfection (Fig. 6).
Although adenovirus is typically considered to be the primary helper
virus of AAV infection, we observed, using double labeling (Cy3Ad and
Cy2AAV-3), little if any interaction or cocompartmentalization of these
particles after the infection process was initiated, whereas double
labeling with two different serotypes of AAV (Cy2AAV-3 and Cy3AAV-2)
demonstrated extensive overlap (Fig. 6A), ruling out technical concerns
about the inability to observe viral Cy2 and Cy3 colocalization. In
addition, these results support the premise that the entry process for
serotype 3 AAV is similar to that established here serotype 2 AAV, and
the mode of entry of the other AAV serotypes may be similar as well,
irrespective of the primary attachment receptor (26).
Studies to address this possibility are currently under way. Although
numerous studies utilizing recombinant AAV vectors for gene delivery
support AAV infection in the absence of adenovirus, these data
demonstrate that adenovirus and AAV traffic through the cell separately
and that adenovirus is unlikely to be in a position to physically assist AAV entry. Therefore, all aspects of adenovirus helper function
must take place after viral infection and passage of the viral particle
through the cell and into the nucleus, in agreement with earlier
studies (33), and are likely solely related to early gene
expression as previously described (10).
To examine the exact mechanism of AAV-2 internalization into cells, we
studied AAV vector-mediated gene transfer with normal and mutant
HeLa cell lines that have reduced capacity for coated-pit-mediated endocytosis (9). These mutant cells overexpressed a
K44A mutant form of dynamin, the cellular protein responsible for
pinching off endocytic invaginations formed during endocytosis. Cells
expressing the mutant dynamin showed a significant decrease in
AAV-mediated gene delivery compared to uninduced cells lacking mutant
dynamin. These findings indicate that efficient AAV entry and infection are both regulated by dynamin, an essential component of the
clathrin-coated pit endocytic pathway. We have previously
shown that entry of AAV into cells is promoted by interaction of the
virus with
v
5 integrin (40).
As has been suggested for adenovirus by Wang et al. (46),
v integrin clustering by viral particles could facilitate localization of AAV to coated pits that are destined for
internalization. Although direct evidence of this is lacking, the
cytoplasmic tail of the
5 subunit of
v
5 integrin contains the NPXY motif
(32, 42), which has been shown to be necessary for the
localization of certain receptors to coated pits (27). By
direct visualization, we observed clustering of AAV particles before
internalization, supporting this concept; however, further studies are
needed to determine whether specific internalization sequences in
v integrins mediate AAV uptake into clathrin-coated pits.
While expression of mutant dynamin significantly inhibited virus gene
delivery, it did not completely abolish this activity. These findings
are consistent with previous reports that the induction of
mutant-dynamin expression does not completely block internalization of
transferrin, epidermal growth factor, or adenovirus, all of which have
been well documented to enter cells via the clathrin-coated pit
pathway. Residual AAV-mediated gene delivery may also represent clathrin-independent entry mechanisms such as fluid-phase pinocytosis, which are not affected by expression of mutant dynamin (21). These aspects of alternative pathways of viral uptake may be
significant in relation to viral vectors and target cells that are not
optimal for wild-type infection. It will be informative to examine
alternative pathways of AAV uptake, both in vitro and in vivo, in
relation to the specificity of AAV vectors.
Biochemical studies using the lysosomotropic drug ammonium chloride
(28) or the proton pump inhibitor bafilomycin A1
(6) showed that these drugs have a significant inhibitory
effect on AAV infectivity. These findings are compatible with the view
that penetration of AAV from the endosome into the cytosol occurs by a
low-pH-dependent mechanism. The finding that neutralization of acidic
organelles had to occur within 30 min after the initiation of
endocytosis suggests that the early endosomal population is the site of
AAV penetration. This notion is further supported by the observation
that 20 nM bafilomycin A1 is able to inhibit AAV-mediated
gene delivery. Previous studies have shown that 20 nM bafilomycin
A1 has no effect on the transport of material from early to
late endosomes and only a modest affect on HeLa cell endosome
acidification (about 0.2 pH units) (5). The fact that 20 nM
bafilomycin A1 blocks AAV infection can be explained by the
pH threshold required for infection. From these data, it appears that a
slight elevation of the endosomal pH is sufficient to prevent AAV infection.
The efficiency of AAV infection suggests that the AAV capsid proteins
alone are able to mediate penetration into the cytosol. Following
release of virus from the endosome, AAV is rapidly trafficked to the
host cell nucleus. Characteristic perinuclear accumulation of AAV
particles is evident within 40 min following the onset of endocytosis.
Based on this distribution, it would appear that AAV might be retained
in the perinuclear recycling endosome compartment. However, our
findings suggest that endosomal escape is complete within this time
frame whereas perinuclear distribution of AAV virions persists
for several hours. The fact that AAV is no longer within an
endosomal compartment is consistent with the observation that AAV
particles are not degraded even after several hours of incubation, as
if they were partitioned away from the proteases which are normally
present in late endosomes or lysosomes.
Earlier studies have suggested that AAV particles can enter the host
cell nucleus via the NPC. Since the maximal nuclear pore size is
approximately 23 nm, it is likely that translocation of AAV (20 to 25 nm in diameter) through the NPC can take place in the absence of
uncoating or major remodeling of the capsid structure. We have provided
evidence, attained via confocal microscopy with Cy3-labeled virions,
that AAV particles are able to enter the nucleus, suggesting that
intact virions enter the nucleus prior to uncoating, although we cannot
determine from these studies if the particles are partially uncoated or
otherwise modified.
In summary, we have established specific points in the AAV infectious
entry pathway which relate to the early steps of viral infection.
Binding to a cell surface receptor initiates internalization through
clathrin-coated pits followed by release of the viral particle into the
cytosol and translocation to the nucleus, where uncoating and gene
expression take place. These aspects of AAV entry can now be expanded
to specific cell types and to vector analysis in vivo. As we obtain a
more detailed molecular picture of the AAV entry process, its
implications in terms of modifying AAV vectors with targeting ligands
will be significantly enhanced.
 |
ACKNOWLEDGMENTS |
The work described here was supported by NIH grants NHLBI 5R01
HL48347-08 and HL51818 (R.J.S.) and Cystic Fibrosis Foundation grants
MARZLU96PO and BARTLE99I0 (J.S.B.).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Children's
Research Institute, Room W531, 700 Children's Dr., Columbus, OH 43205. Phone: (614) 722-2683. Fax: (614) 722-3273. E-mail:
BartletJ{at}pediatrics.ohio-state.edu.
 |
REFERENCES |
| 1.
|
Bartlett, J. S., and R. J. Samulski.
1998.
Fluorescent viral vectors: a new technique for the pharmacological analysis of gene therapy.
Nat. Med.
4:635-637[CrossRef][Medline].
|
| 2.
|
Bartlett, J. S.,
R. J. Samulski, and T. J. McCown.
1998.
Selective and rapid uptake of adeno-associated virus type-2 (AAV-2) in brain.
Hum. Gene Ther.
9:1181-1186[Medline].
|
| 3.
|
Basak, S.,
H. Turner, and S. Parr.
1994.
Identification of a 40- to 42-kDa attachment polypeptide for canine parvovirus in A72 cells.
Virology
205:7-16[CrossRef][Medline].
|
| 4.
|
Basak, S., and H. Turner.
1992.
Infectious entry pathway for canine parvovirus.
Virology
186:368-376[CrossRef][Medline].
|
| 5.
|
Bayer, N.,
D. Schober,
E. Prchla,
R. F. Murphy,
D. Blaas, and R. Fuchs.
1998.
Effect of bafilomycin A1 and nocodazole on endocytic transport in HeLa cells: implications for viral uncoating and infection.
J. Virol.
72:9645-9655[Abstract/Free Full Text].
|
| 6.
|
Bowman, E. J.,
A. Siebers, and K. Altendorf.
1988.
Bafilomycins: a class of inhibitors of membrane ATPases from microorganisms, animal cells, and plant cells.
Proc. Natl. Acad. Sci. USA
85:7972-7976[Abstract/Free Full Text].
|
| 7.
|
Chiu, C. Y.,
P. Mathias,
G. R. Nemerow, and P. L. Stewart.
1999.
Structure of adenovirus complexed with its internalization receptor, v 5 integrin.
J. Virol.
73:6759-6768[Abstract/Free Full Text].
|
| 8.
|
Clark, K. R.,
X. Liu,
J. P. McGrath, and P. R. Johnson.
1999.
Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses.
Hum. Gene Ther.
10:1031-1039[CrossRef][Medline].
|
| 9.
|
Damke, H.,
T. Baba,
D. E. Warnock, and S. L. Schmid.
1994.
Induction of mutant dynamin specifically blocks endocytic coated vesicle formation.
J. Cell Biol.
127:915-934[Abstract/Free Full Text].
|
| 10.
|
Ferrari, F. K.,
T. Samulski,
T. Shenk, and R. J. Samulski.
1996.
Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors.
J. Virol.
70:3227-3234[Abstract].
|
| 11.
|
Fisher, K. J.,
G.-P. Gao,
M. D. Weitzman,
R. DeMatteo,
J. F. Burda, and J. M. Wilson.
1996.
Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis.
J. Virol.
70:520-532[Abstract].
|
| 12.
|
Gey, G. O.,
W. D. Coffman, and M. T. Kubicek.
1952.
Tissue culture studies of the proliferative capacity of cervical carcinoma and normal epithelium.
Cancer Res.
12L:264.
|
| 13.
|
Goodman, S.,
X. Xiao,
R. E. Donahue,
A. Moulton,
J. Miller,
C. Walsh,
N. S. Young,
R. J. Samulski, and A. W. Nienhuis.
1994.
Recombinant adeno-associated virus-mediated gene transfer into hematopoietic progenitor cells.
Blood
84:1492-1500[Abstract/Free Full Text].
|
| 14.
|
Graham, F. L.,
J. Smiley,
W. C. Russell, and R. Nairn.
1977.
Characteristics of a human cell line transformed by DNA from human adenovirus type 5.
J. Gen. Virol.
36:59-74[Abstract/Free Full Text].
|
| 15.
|
Greber, U. F.,
M. Y. Nakano, and M. Suomalainen.
1998.
Adenovirus entry into cells. A quantitative fluorescence microscopy approach, p. 217-230.
In
W. S. M. Wold (ed.), Adenovirus methods and protocols, vol. 21. Humana Press, Inc., Totowa, N.J.
|
| 16.
|
Greber, U. F.,
M. Suomalainen,
R. P. Stidwill,
K. Boucke,
M. W. Ebersold, and A. Helenius.
1997.
The role of the nuclear pore complex in adenovirus DNA entry.
EMBO J.
16:5998-6007[CrossRef][Medline].
|
| 17.
|
Halbert, C. L.,
T. A. Standaert,
M. L. Aitken,
I. E. Alexander,
D. W. Russell, and A. D. Miller.
1997.
Transduction by adeno-associated virus vectors in the rabbit airway: efficiency, persistence, and readministration.
J. Virol.
71:5932-5941[Abstract].
|
| 18.
|
Hinshaw, J. E., and S. L. Schmid.
1995.
Dynamin self-assembles into rings suggesting a mechanism for coated vesicle budding.
Nature
374:190-192[CrossRef][Medline].
|
| 19.
|
Jones, N., and T. Shenk.
1979.
Isolation of adenovirus type 5 host range deletion mutants defective for transformation of rat embryo cells.
Cell
17:683-689[CrossRef][Medline].
|
| 20.
|
Kaljot, K. T.,
R. D. Shaw,
D. H. Rubin, and H. B. Greenberg.
1988.
Infectious rotavirus enters cells by direct cell membrane penetration, not by endocytosis.
J. Virol.
62:1136-1144[Abstract/Free Full Text].
|
| 21.
|
Lamaze, C., and S. L. Schmid.
1995.
The emergence of clathrin-independent pinocytic pathways.
Curr. Opin. Cell Biol.
7:573-580[CrossRef][Medline].
|
| 22.
|
Leopold, P. L.,
B. Ferris,
I. Grinberg,
S. Worgall,
N. R. Hackett, and R. G. Crystal.
1998.
Fluorescent virions: dynamic trafficking of the pathway of adenoviral gene transfer vectors in living cells.
Hum. Gene Ther.
9:367-378[Medline].
|
| 23.
|
Li, J.,
R. J. Samulski, and X. Xiao.
1997.
Role for highly regulated rep gene expression in adeno-associated virus vector production.
J. Virol.
71:5236-5243[Abstract].
|
| 24.
|
Linser, P.,
H. Bruning, and R. W. Armentrout.
1977.
Specific binding sites for a parvovirus, minute virus of mice, on cultured mouse cells.
J. Virol.
24:211-221[Abstract/Free Full Text].
|
| 25.
|
Madshus, I. H.,
S. Olsner, and K. Sandvig.
1984.
Mechanism of entry into the cytosol of poliovirus type 1: requirement of low pH.
J. Cell Biol.
98:1194-1200[Abstract/Free Full Text].
|
| 26.
|
Mizukami, H.,
N. S. Young, and K. E. Brown.
1996.
Adeno-associated virus type 2 binds to a 150-kilodalton cell membrane glycoprotein.
Virology
217:124-130[CrossRef][Medline].
|
| 27.
|
Mukherjee, S.,
R. N. Ghosh, and F. R. Maxfield.
1997.
Endocytosis.
Physiol. Rev.
77:759-803[Abstract/Free Full Text].
|
| 28.
|
Ohkuma, S., and B. Poole.
1978.
Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents.
Proc. Natl. Acad. Sci. USA
75:3327-3331[Abstract/Free Full Text].
|
| 29.
|
Pastan, I.,
P. Seth,
D. Fitzgerald, and M. Willingham.
1986.
Adenovirus entry into cells: some new observations on an old problem, p. 141-146.
In
L. Notkin, and M. B. A. Oldstone (ed.), Concepts in viral pathogenesis II. Springer-Verlag, New York, N.Y.
|
| 30.
|
Qing, K.,
C. Mah,
J. Hansen,
S. Zhou,
V. Dwarki, and A. Srivastava.
1999.
Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2.
Nat. Med.
5:71-77[CrossRef][Medline].
|
| 31.
|
Qing, K.,
B. Khuntirat,
C. Mah,
D. M. Kube,
X.-S. Wang,
S. Ponnazhagan,
S. Zhou,
V. J. Dwarki,
M. C. Yoder, and A. Srivastava.
1998.
Adeno-associated virus type 2-mediated gene transfer: correlation of tyrosine phosphorylation of the cellular single-stranded D sequence-binding protein with transgene expression in human cells in vitro and murine tissues in vivo.
J. Virol.
72:1593-1599[Abstract/Free Full Text].
|
| 32.
|
Ramaswamy, H., and M. E. Hemler.
1990.
Cloning, primary structure and properties of a novel human integrin beta subunit.
EMBO J.
9:1561-1568[Medline].
|
| 33.
|
Rose, J. A., and F. Koczot.
1972.
Adenovirus-associated virus multiplication. VII. Helper requirement for viral deoxyribonucleic acid and ribonucleic acid synthesis.
J. Virol.
10:1-8[Abstract/Free Full Text].
|
| 34.
|
Samulski, R. J.,
L.-S. Chang, and T. Shenk.
1989.
Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression.
J. Virol.
63:3822-3828[Abstract/Free Full Text].
|
| 35.
|
Samulski, R. J.,
L.-S. Chang, and T. Shenk.
1987.
A recombinant plasmid from which an infectious adeno-associated virus genome can be excised in vitro and its use to study viral replication.
J. Virol.
61:3096-3101[Abstract/Free Full Text].
|
| 36.
|
Samulski, R. J.,
M. Sally, and N. Muzyczka.
1999.
Adeno-associated viral vectors, p. 131-172.
In
T. Friedmann (ed.), The development of human gene therapy. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
|
| 37.
|
Sanes, J. R.,
J. L. R. Rubenstein, and J. F. Nicolas.
1986.
Use of a recombinant retrovirus to study post-implantation cell lineage in mouse embryos.
EMBO J.
5:3133-3142[Medline].
|
| 38.
|
Snyder, R. O.,
X. Xiao, and R. J. Samulski.
1996.
Production of recombinant adeno-associated virus vectors, p. 12.1.1-12.2.23.
In
N. Dracopoli, J. Haines, B. Krof, D. Moir, C. Seidman, and J. S. Seidman (ed.), Current protocols in human genetics. John Wiley & Sons, New York, N.Y.
|
| 39.
|
Sturzenbecker, L. J.,
M. Nibert,
D. Furlong, and B. N. Fields.
1987.
Intracellular digestion of reovirus particles requires a low pH and is an essential step in the viral infectious cycle.
J. Virol.
61:2351-2361[Abstract/Free Full Text].
|
| 40.
|
Summerford, C.,
J. S. Bartlett, and R. J. Samulski.
1999.
V 5 integrin: a co-receptor for adeno-associated virus type 2 infection.
Nat. Med.
5:78-82[CrossRef][Medline].
|
| 41.
|
Summerford, C., and R. J. Samulski.
1998.
Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions.
J. Virol.
72:1438-1445[Abstract/Free Full Text].
|
| 42.
|
Suzuki, S.,
W. S. Argraves,
R. Pytela,
H. Arai,
T. Krusius,
M. D. Pierschbacher, and E. Ruoslahti.
1986.
cDNA and amino acid sequences of the cell adhesion protein receptor recognizing vitronectin reveal a transmembrane domain and homologies with other adhesion protein receptors.
Proc. Natl. Acad. Sci. USA
83:8614-8618[Abstract/Free Full Text].
|
| 43.
|
Takei, K.,
P. S. McPherson,
S. L. Schmid, and P. D. Camilli.
1995.
Tubular membrane invaginations coated by dynamin rings are induced by GTP- S in nerve terminals.
Nature
374:186-190[CrossRef][Medline].
|
| 44.
|
Teramoto, S.,
J. S. Bartlett,
D. McCarty,
X. Xiao,
R. J. Samulski, and R. C. Boucher.
1998.
Factors influencing adeno-associated virus-mediated gene transfer to human cystic fibrosis airway epithelial cells: comparison with adenovirus vectors.
J. Virol.
72:8904-8912[Abstract/Free Full Text].
|
| 45.
|
Varga, M. J.,
C. Weibull, and E. Everitt.
1991.
Infectious entry pathway of adenovirus type 2.
J. Virol.
65:6061-6070[Abstract/Free Full Text].
|
| 46.
|
Wang, K.,
S. Huang,
A. Kapoor-Munshi, and G. Nemerow.
1998.
Adenovirus internalization and infection require dynamin.
J. Virol.
72:3455-3458[Abstract/Free Full Text].
|
| 47.
|
Wickham, T. J.,
E. J. Filardo,
D. A. Cheresh, and G. R. Nemerow.
1994.
Integrin v 5 selectively promotes adenovirus-mediated cell membrane permeabilization.
J. Cell Biol.
127:257-264[Abstract/Free Full Text].
|
| 48.
|
Zeichhardt, H.,
K. Wertz,
P. Willingman, and K.-O. Habermehl.
1985.
Entry of poliovirus type 1 and mouse Elberfeld (ME) virus into HEp-2 cells: receptor-mediated endocytosis and endosomal or lysosomal uncoating.
J. Gen. Virol.
66:483-492[Abstract/Free Full Text].
|
| 49.
|
Zolotukhin, S.
1999.
Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield.
Gene Ther.
6:973-985[CrossRef][Medline].
|
Journal of Virology, March 2000, p. 2777-2785, Vol. 74, No. 6
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Vendeville, A., Ravallec, M., Jousset, F.-X., Devise, M., Mutuel, D., Lopez-Ferber, M., Fournier, P., Dupressoir, T., Ogliastro, M.
(2009). Densovirus Infectious Pathway Requires Clathrin-Mediated Endocytosis Followed by Trafficking to the Nucleus. J. Virol.
83: 4678-4689
[Abstract]
[Full Text]
-
Johnson, J. S., Samulski, R. J.
(2009). Enhancement of Adeno-Associated Virus Infection by Mobilizing Capsids into and Out of the Nucleolus. J. Virol.
83: 2632-2644
[Abstract]
[Full Text]
-
Bantel-Schaal, U., Braspenning-Wesch, I., Kartenbeck, J.
(2009). Adeno-associated virus type 5 exploits two different entry pathways in human embryo fibroblasts. J. Gen. Virol.
90: 317-322
[Abstract]
[Full Text]
-
Daya, S., Berns, K. I.
(2008). Gene Therapy Using Adeno-Associated Virus Vectors. Clin. Microbiol. Rev.
21: 583-593
[Abstract]
[Full Text]
-
Atasoy, D., Aponte, Y., Su, H. H., Sternson, S. M.
(2008). A FLEX Switch Targets Channelrhodopsin-2 to Multiple Cell Types for Imaging and Long-Range Circuit Mapping. J. Neurosci.
28: 7025-7030
[Full Text]
-
DiPrimio, N., Asokan, A., Govindasamy, L., Agbandje-McKenna, M., Samulski, R. J.
(2008). Surface Loop Dynamics in Adeno-Associated Virus Capsid Assembly. J. Virol.
82: 5178-5189
[Abstract]
[Full Text]
-
Cervelli, T., Palacios, J. A., Zentilin, L., Mano, M., Schwartz, R. A., Weitzman, M. D., Giacca, M.
(2008). Processing of recombinant AAV genomes occurs in specific nuclear structures that overlap with foci of DNA-damage-response proteins. J. Cell Sci.
121: 349-357
[Abstract]
[Full Text]
-
Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., Chiorini, J. A.
(2008). Adeno-Associated Virus Type 12 (AAV12): a Novel AAV Serotype with Sialic Acid- and Heparan Sulfate Proteoglycan-Independent Transduction Activity. J. Virol.
82: 1399-1406
[Abstract]
[Full Text]
-
Cearley, C. N., Wolfe, J. H.
(2007). A Single Injection of an Adeno-Associated Virus Vector into Nuclei with Divergent Connections Results in Widespread Vector Distribution in the Brain and Global Correction of a Neurogenetic Disease. J. Neurosci.
27: 9928-9940
[Abstract]
[Full Text]
-
Liang, C.-m., Zhong, C.-p., Sun, R.-x., Liu, B.-b., Huang, C., Qin, J., Zhou, S., Shan, J., Liu, Y.-k., Ye, S.-l.
(2007). Local Expression of Secondary Lymphoid Tissue Chemokine Delivered by Adeno-Associated Virus within the Tumor Bed Stimulates Strong Anti-Liver Tumor Immunity. J. Virol.
81: 9502-9511
[Abstract]
[Full Text]
-
Wang, J., Xie, J., Lu, H., Chen, L., Hauck, B., Samulski, R. J., Xiao, W.
(2007). Existence of transient functional double-stranded DNA intermediates during recombinant AAV transduction. Proc. Natl. Acad. Sci. USA
104: 13104-13109
[Abstract]
[Full Text]
-
Ren, C., White, A. F., Ponnazhagan, S.
(2007). Notch1 Augments Intracellular Trafficking of Adeno-Associated Virus Type 2. J. Virol.
81: 2069-2073
[Abstract]
[Full Text]
-
Cantin, C., Holguera, J., Ferreira, L., Villar, E., Munoz-Barroso, I.
(2007). Newcastle disease virus may enter cells by caveolae-mediated endocytosis. J. Gen. Virol.
88: 559-569
[Abstract]
[Full Text]
-
Sonntag, F., Bleker, S., Leuchs, B., Fischer, R., Kleinschmidt, J. A.
(2006). Adeno-Associated Virus Type 2 Capsids with Externalized VP1/VP2 Trafficking Domains Are Generated prior to Passage through the Cytoplasm and Are Maintained until Uncoating Occurs in the Nucleus. J. Virol.
80: 11040-11054
[Abstract]
[Full Text]
-
Cohen, S., Behzad, A. R., Carroll, J. B., Pante, N.
(2006). Parvoviral nuclear import: bypassing the host nuclear-transport machinery.. J. Gen. Virol.
87: 3209-3213
[Abstract]
[Full Text]
-
Kelkar, S., De, B. P., Gao, G., Wilson, J. M., Crystal, R. G., Leopold, P. L.
(2006). A Common Mechanism for Cytoplasmic Dynein-Dependent Microtubule Binding Shared among Adeno-Associated Virus and Adenovirus Serotypes.. J. Virol.
80: 7781-7785
[Abstract]
[Full Text]
-
Grieger, J. C., Snowdy, S., Samulski, R. J.
(2006). Separate Basic Region Motifs within the Adeno-Associated Virus Capsid Proteins Are Essential for Infectivity and Assembly.. J. Virol.
80: 5199-5210
[Abstract]
[Full Text]
-
Murray, S., Nilsson, C. L., Hare, J. T., Emmett, M. R., Korostelev, A., Ongley, H., Marshall, A. G., Chapman, M. S.
(2006). Characterization of the Capsid Protein Glycosylation of Adeno-Associated Virus Type 2 by High-Resolution Mass Spectrometry.. J. Virol.
80: 6171-6176
[Abstract]
[Full Text]
-
Mani, B., Baltzer, C., Valle, N., Almendral, J. M., Kempf, C., Ros, C.
(2006). Low pH-Dependent Endosomal Processing of the Incoming Parvovirus Minute Virus of Mice Virion Leads to Externalization of the VP1 N-Terminal Sequence (N-VP1), N-VP2 Cleavage, and Uncoating of the Full-Length Genome. J. Virol.
80: 1015-1024
[Abstract]
[Full Text]
-
Cohen, S., Pante, N.
(2005). Pushing the envelope: microinjection of Minute virus of mice into Xenopus oocytes causes damage to the nuclear envelope. J. Gen. Virol.
86: 3243-3252
[Abstract]
[Full Text]
-
Jin, S., Zhang, B., Weisz, O. A., Montelaro, R. C.
(2005). Receptor-Mediated Entry by Equine Infectious Anemia Virus Utilizes a pH-Dependent Endocytic Pathway. J. Virol.
79: 14489-14497
[Abstract]
[Full Text]
-
Lux, K., Goerlitz, N., Schlemminger, S., Perabo, L., Goldnau, D., Endell, J., Leike, K., Kofler, D. M., Finke, S., Hallek, M., Buning, H.
(2005). Green Fluorescent Protein-Tagged Adeno-Associated Virus Particles Allow the Study of Cytosolic and Nuclear Trafficking. J. Virol.
79: 11776-11787
[Abstract]
[Full Text]
-
Misinzo, G., Meerts, P., Bublot, M., Mast, J., Weingartl, H. M., Nauwynck, H. J.
(2005). Binding and entry characteristics of porcine circovirus 2 in cells of the porcine monocytic line 3D4/31. J. Gen. Virol.
86: 2057-2068
[Abstract]
[Full Text]
-
Kronenberg, S., Bottcher, B., von der Lieth, C. W., Bleker, S., Kleinschmidt, J. A.
(2005). A Conformational Change in the Adeno-Associated Virus Type 2 Capsid Leads to the Exposure of Hidden VP1 N Termini. J. Virol.
79: 5296-5303
[Abstract]
[Full Text]
-
Bleker, S., Sonntag, F., Kleinschmidt, J. A.
(2005). Mutational Analysis of Narrow Pores at the Fivefold Symmetry Axes of Adeno-Associated Virus Type 2 Capsids Reveals a Dual Role in Genome Packaging and Activation of Phospholipase A2 Activity. J. Virol.
79: 2528-2540
[Abstract]
[Full Text]
-
Kashiwakura, Y., Tamayose, K., Iwabuchi, K., Hirai, Y., Shimada, T., Matsumoto, K., Nakamura, T., Watanabe, M., Oshimi, K., Daida, H.
(2005). Hepatocyte Growth Factor Receptor Is a Coreceptor for Adeno-Associated Virus Type 2 Infection. J. Virol.
79: 609-614
[Abstract]
[Full Text]
-
Hauck, B., Zhao, W., High, K., Xiao, W.
(2004). Intracellular Viral Processing, Not Single-Stranded DNA Accumulation, Is Crucial for Recombinant Adeno-Associated Virus Transduction. J. Virol.
78: 13678-13686
[Abstract]
[Full Text]
-
Hojo, M., Abe, T., Sugano, E., Yoshioka, Y., Saigo, Y., Tomita, H., Wakusawa, R., Tamai, M.
(2004). Photoreceptor Protection by Iris Pigment Epithelial Transplantation Transduced with AAV-Mediated Brain-Derived Neurotrophic Factor Gene. IOVS
45: 3721-3726
[Abstract]
[Full Text]
-
Chu, J. J. H., Ng, M. L.
(2004). Infectious Entry of West Nile Virus Occurs through a Clathrin-Mediated Endocytic Pathway. J. Virol.
78: 10543-10555
[Abstract]
[Full Text]
-
Hamilton, H., Gomos, J., Berns, K. I., Falck-Pedersen, E.
(2004). Adeno-Associated Virus Site-Specific Integration and AAVS1 Disruption. J. Virol.
78: 7874-7882
[Abstract]
[Full Text]
-
Vihinen-Ranta, M., Suikkanen, S., Parrish, C. R.
(2004). Pathways of Cell Infection by Parvoviruses and Adeno-Associated Viruses. J. Virol.
78: 6709-6714
[Full Text]
-
Peden, C. S., Burger, C., Muzyczka, N., Mandel, R. J.
(2004). Circulating Anti-Wild-Type Adeno-Associated Virus Type 2 (AAV2) Antibodies Inhibit Recombinant AAV2 (rAAV2)-Mediated, but Not rAAV5-Mediated, Gene Transfer in the Brain. J. Virol.
78: 6344-6359
[Abstract]
[Full Text]
-
Hueffer, K., Palermo, L. M., Parrish, C. R.
(2004). Parvovirus Infection of Cells by Using Variants of the Feline Transferrin Receptor Altering Clathrin-Mediated Endocytosis, Membrane Domain Localization, and Capsid-Binding Domains. J. Virol.
78: 5601-5611
[Abstract]
[Full Text]
-
Rabinowitz, J. E., Bowles, D. E., Faust, S. M., Ledford, J. G., Cunningham, S. E., Samulski, R. J.
(2004). Cross-Dressing the Virion: the Transcapsidation of Adeno-Associated Virus Serotypes Functionally Defines Subgroups. J. Virol.
78: 4421-4432
[Abstract]
[Full Text]
-
Zhong, L., Qing, K., Si, Y., Chen, L., Tan, M., Srivastava, A.
(2004). Heat-shock Treatment-mediated Increase in Transduction by Recombinant Adeno-associated Virus 2 Vectors Is Independent of the Cellular Heat-shock Protein 90. J. Biol. Chem.
279: 12714-12723
[Abstract]
[Full Text]
-
Yan, Z., Zak, R., Zhang, Y., Ding, W., Godwin, S., Munson, K., Peluso, R., Engelhardt, J. F.
(2004). Distinct Classes of Proteasome-Modulating Agents Cooperatively Augment Recombinant Adeno-Associated Virus Type 2 and Type 5-Mediated Transduction from the Apical Surfaces of Human Airway Epithelia. J. Virol.
78: 2863-2874
[Abstract]
[Full Text]
-
Thomas, C. E., Storm, T. A., Huang, Z., Kay, M. A.
(2004). Rapid Uncoating of Vector Genomes Is the Key to Efficient Liver Transduction with Pseudotyped Adeno-Associated Virus Vectors. J. Virol.
78: 3110-3122
[Abstract]
[Full Text]
-
Rabe, B., Vlachou, A., Pante, N., Helenius, A., Kann, M.
(2003). Nuclear import of hepatitis B virus capsids and release of the viral genome. Proc. Natl. Acad. Sci. USA
100: 9849-9854
[Abstract]
[Full Text]
-
Passini, M. A., Watson, D. J., Vite, C. H., Landsburg, D. J., Feigenbaum, A. L., Wolfe, J. H.
(2003). Intraventricular Brain Injection of Adeno-Associated Virus Type 1 (AAV1) in Neonatal Mice Results in Complementary Patterns of Neuronal Transduction to AAV2 and Total Long-Term Correction of Storage Lesions in the Brains of {beta}-Glucuronidase-Deficient Mice. J. Virol.
77: 7034-7040
[Abstract]
[Full Text]
-
Suh, J., Wirtz, D., Hanes, J.
(2003). Efficient active transport of gene nanocarriers to the cell nucleus. Proc. Natl. Acad. Sci. USA
100: 3878-3882
[Abstract]
[Full Text]
-
Bousarghin, L., Touze, A., Sizaret, P.-Y., Coursaget, P.
(2003). Human Papillomavirus Types 16, 31, and 58 Use Different Endocytosis Pathways To Enter Cells. J. Virol.
77: 3846-3850
[Abstract]
[Full Text]
-
Mannova, P., Forstova, J.
(2003). Mouse Polyomavirus Utilizes Recycling Endosomes for a Traffic Pathway Independent of COPI Vesicle Transport. J. Virol.
77: 1672-1681
[Abstract]
[Full Text]
-
Ros, C., Burckhardt, C. J., Kempf, C.
(2002). Cytoplasmic Trafficking of Minute Virus of Mice: Low-pH Requirement, Routing to Late Endosomes, and Proteasome Interaction. J. Virol.
76: 12634-12645
[Abstract]
[Full Text]
-
Ponnazhagan, S., Mahendra, G., Kumar, S., Thompson, J. A., Castillas, M. Jr.
(2002). Conjugate-Based Targeting of Recombinant Adeno-Associated Virus Type 2 Vectors by Using Avidin-Linked Ligands. J. Virol.
76: 12900-12907
[Abstract]
[Full Text]
-
Xiao, W., Warrington, K. H. Jr., Hearing, P., Hughes, J., Muzyczka, N.
(2002). Adenovirus-Facilitated Nuclear Translocation of Adeno-Associated Virus Type 2. J. Virol.
76: 11505-11517
[Abstract]
[Full Text]
-
Pajusola, K., Gruchala, M., Joch, H., Luscher, T. F., Yla-Herttuala, S., Bueler, H.
(2002). Cell-Type-Specific Characteristics Modulate the Transduction Efficiency of Adeno-Associated Virus Type 2 and Restrain Infection of Endothelial Cells. J. Virol.
76: 11530-11540
[Abstract]
[Full Text]
-
Goncalves, M. A. F. V., van der Velde, I., Janssen, J. M., Maassen, B. T. H., Heemskerk, E. H., Opstelten, D.-J. E., Knaan-Shanzer, S., Valerio, D., de Vries, A. A. F.
(2002). Efficient Generation and Amplification of High-Capacity Adeno-Associated Virus/Adenovirus Hybrid Vectors. J. Virol.
76: 10734-10744
[Abstract]
[Full Text]
-
Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., Chapman, M. S.
(2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA
99: 10405-10410
[Abstract]
[Full Text]
-
Sieczkarski, S. B., Whittaker, G. R.
(2002). Dissecting virus entry via endocytosis. J. Gen. Virol.
83: 1535-1545
[Abstract]
[Full Text]
-
Suikkanen, S., Saajarvi, K., Hirsimaki, J., Valilehto, O., Reunanen, H., Vihinen-Ranta, M., Vuento, M.
(2002). Role of Recycling Endosomes and Lysosomes in Dynein-Dependent Entry of Canine Parvovirus. J. Virol.
76: 4401-4411
[Abstract]
[Full Text]
-
Zaiss, A.-K., Liu, Q., Bowen, G. P., Wong, N. C. W., Bartlett, J. S., Muruve, D. A.
(2002). Differential Activation of Innate Immune Responses by Adenovirus and Adeno-Associated Virus Vectors. J. Virol.
76: 4580-4590
[Abstract]
[Full Text]
-
Bantel-Schaal, U., Hub, B., Kartenbeck, J.
(2002). Endocytosis of Adeno-Associated Virus Type 5 Leads to Accumulation of Virus Particles in the Golgi Compartment. J. Virol.
76: 2340-2349
[Abstract]
[Full Text]
-
Rabinowitz, J. E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., Samulski, R. J.
(2002). Cross-Packaging of a Single Adeno-Associated Virus (AAV) Type 2 Vector Genome into Multiple AAV Serotypes Enables Transduction with Broad Specificity. J. Virol.
76: 791-801
[Abstract]
[Full Text]
-
Zentilin, L., Marcello, A., Giacca, M.
(2001). Involvement of Cellular Double-Stranded DNA Break Binding Proteins in Processing of the Recombinant Adeno-Associated Virus Genome. J. Virol.
75: 12279-12287
[Abstract]
[Full Text]
-
Passini, M. A., Wolfe, J. H.
(2001). Widespread Gene Delivery and Structure-Specific Patterns of Expression in the Brain after Intraventricular Injections of Neonatal Mice with an Adeno-Associated Virus Vector. J. Virol.
75: 12382-12392
[Abstract]
[Full Text]
-
Seisenberger, G., Ried, M. U., Endre{beta}, T., Buning, H., Hallek, M., Brauchle, C.
(2001). Real-Time Single-Molecule Imaging of the Infection Pathway of an Adeno-Associated Virus. Science
294: 1929-1932
[Abstract]
[Full Text]
-
Richterova, Z., Liebl, D., Horak, M., Palkova, Z., Hozak, P., Korb, J., Forstova, J.
(2001). Caveolae Are Involved in the Trafficking of Mouse Polyomavirus Virions and Artificial VP1 Pseudocapsids toward Cell Nuclei. J. Virol.
75: 10880-10891
[Abstract]
[Full Text]
-
Ponnazhagan, S., Curiel, D. T., Shaw, D. R., Alvarez, R. D., Siegal, G. P.
(2001). Adeno-associated Virus for Cancer Gene Therapy. Cancer Res.
61: 6313-6321
[Full Text]
-
Hansen, J., Qing, K., Srivastava, A.
(2001). Adeno-Associated Virus Type 2-Mediated Gene Transfer: Altered Endocytic Processing Enhances Transduction Efficiency in Murine Fibroblasts. J. Virol.
75: 4080-4090
[Abstract]
[Full Text]
-
Weigel-Kelley, K. A., Yoder, M. C., Srivastava, A.
(2001). Recombinant Human Parvovirus B19 Vectors: Erythrocyte P Antigen Is Necessary but Not Sufficient for Successful Transduction of Human Hematopoietic Cells. J. Virol.
75: 4110-4116
[Abstract]
[Full Text]
-
Douar, A.-M., Poulard, K., Stockholm, D., Danos, O.
(2001). Intracellular Trafficking of Adeno-Associated Virus Vectors: Routing to the Late Endosomal Compartment and Proteasome Degradation. J. Virol.
75: 1824-1833
[Abstract]
[Full Text]
-
Sanlioglu, S., Benson, P. K., Yang, J., Atkinson, E. M., Reynolds, T., Engelhardt, J. F.
(2000). Endocytosis and Nuclear Trafficking of Adeno-Associated Virus Type 2 Are Controlled by Rac1 and Phosphatidylinositol-3 Kinase Activation. J. Virol.
74: 9184-9196
[Abstract]
[Full Text]
-
Wobus, C. E., Hügle-Dörr, B., Girod, A., Petersen, G., Hallek, M., Kleinschmidt, J. A.
(2000). Monoclonal Antibodies against the Adeno-Associated Virus Type 2 (AAV-2) Capsid: Epitope Mapping and Identification of Capsid Domains Involved in AAV-2-Cell Interaction and Neutralization of AAV-2 Infection. J. Virol.
74: 9281-9293
[Abstract]
[Full Text]